# Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine

> **NCT05201352** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Georges Francois Leclerc** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** trifluridine/tipiracil + XB2001
- **DRUG:** trifluridine/tipiracil + placebo

## Key facts

- **NCT ID:** NCT05201352
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-13
- **Primary completion:** 2026-10-13
- **Final completion:** 2026-10-13
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201352, "Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05201352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*